QRxPharma Announces Strategic Partnership with Actavis; Agreement for U.S. Sales of MoxDuo( IR to Address the $2.5 Billion Acute Pain Market in 2012

SYDNEY and BEDMINSTER, New Jersey, December 21, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a binding Letter of Intent (LOI) with Actavis Inc. for the formation of a strategic partnership to commercialise MoxDuo IR in the U.S. acute pain marketplace. MoxDuo IR is a patented 3:2 ratio fixed dose combination of morphine and oxycodone.  Actavis Inc. is a subsidiary of Actavis Group, hf a privately held company based in Europe with 10,000 employ...continued QRXPY

URL: http://www.investorpoint.com/news/INTHPINK/47037518/